(BUSINESS WIRE)--Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnosis company, today announced Dr. Thomas Taapken as new Chief Financial Officer (CFO) succeeding the company’s current CFO Oliver Schacht, PhD, effective April 1st, 2011. As previously announced in December 2010, Oliver Schacht will leave effective March 31st, 2011. Oliver Schacht and Thomas Taapken will work closely together to ensure an ordered and structured transition during Q1 2011.
